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Abstract A variety of anthropogenic compounds has been
found to be capable of disrupting the endocrine systems of
organisms, in laboratory studies as well as in wildlife. The
most widely described endpoint is estrogenicity, but other
hormonal disturbances, e.g., thyroid hormone disruption, are
gaining more and more attention. Here, we present a review
and chemical characterization, using principal component
analysis, of organic compounds that have been tested for their
capacity to bind competitively to the thyroid hormone trans-
port protein transthyretin (TTR). The database contains 250
individual compounds and technical mixtures, of which 144
compounds are defined as TTR binders. Almost one third of
these compounds (n=52) were even more potent than the
natural hormone thyroxine (T4). The database was used as a
tool to assist in the identification of thyroid hormone-disrupting
compounds (THDCs) in an effect-directed analysis (EDA)
study of a sediment sample. Two compounds could be con-
firmed to contribute to the detected TTR-binding potency in
the sediment sample, i.e., triclosan and nonylphenol technical
mixture. They constituted less than 1 % of the TTR-binding
potency of the unfractionated extract. The low rate of explained
activity may be attributed to the challenges related to identifi-
cation of unknown contaminants in combination with the
limited knowledge about THDCs in general. This study
demonstrates the need for databases containing compound-
specific toxicological properties. In the framework of EDA,
such a database could be used to assist in the identification and
confirmation of causative compounds focusing on thyroid
hormone disruption.
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Introduction
Both anthropogenic and naturally occurring compounds
that are widely spread in the environment have the poten-
tial to disrupt the endocrine system of organisms. Report-
ed impacts of endocrine-disrupting compounds (EDCs) in
wildlife are, e.g., decreased fertility, altered masculinity
and femininity, compromised immune system, gross birth
defects, and thyroid dysfunctions [1]. Thyroid hormones
(TH) play an important role in the (embryonic) devel-
opment and in the maintenance of a normal physiolog-
ical state. Compounds in the environment that have TH-
disrupting properties could have devastating effects on individ-
uals as well as on whole populations. Therefore, it is important
to identify thyroid hormone-disrupting compounds (THDCs)
and to construct screening methodologies to be included in
monitoring programs [2].
TH disruption can be caused through many different path-
ways, such as interferencewith THmetabolism, TH excretion,
or TH transport [3–5]. In 2006, a review paper on TH
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disruption assays was published by the Organisation for Eco-
nomic Co-operation and Development (OECD) [3], and in
2010, it was proposed to establish a thyroid scoping effort
group (TSEG) to determine the state of in vitro thyroid assays
since 2006. The purpose of the TSEG was to bring relevant
in vitro thyroid assays to the attention of OECD member
countries and provide recommendations for their development
and use [2]. Out of the 18 assays reviewed, the top three of the
selected assays focused on TH disruption via transport protein
binding [3]. Available in vitro assays identifying THDCs
on a mechanism-base have been thoroughly discussed in
a recently published review [6]. This study also recom-
mended using disrupted circulation and transport of TH
via the binding to serum transport proteins for the evalua-
tion of the TH-disrupting potency of compounds.
Thyroid hormones are lipophilic compounds that are poor-
ly soluble in aqueous media, including blood plasma. There-
fore, TH transport proteins that are present in the plasma are
important as they increase the blood carrying capacity for TH.
TH transport proteins are themselves regulated by TH; thus,
compounds that change circulating levels of TH are also likely
to alter the transport protein concentration which will further
change the dynamics of this endocrine system [3, 6]. Verte-
brates typically have three major TH transport proteins, i.e.,
transthyretin (TTR), thyroxine-binding globulin (TBG), and
albumin. In general, these TH transport proteins have higher
affinity for the precursor TH hormone thyroxine (T4), which is
therefore considered as the transport form of TH, than for 3,3′,
5-triiodothyronine (T3), which is the active form of TH after
deiodination of T4. Although mammalian TTR indeed has
higher affinity for T4, TTR from teleost fish, amphibians, rep-
tiles, and birds has higher affinity for T3 than for T4 [7]. Also,
the relative importance of the three TH transporter proteins
differs per species. Whereas TBG carries about 75 % of the
TH in humans, TTR is the most important TH-transporting
protein in rodents, tadpoles, and fish. Albumin is a nonselec-
tive transport protein for hormones. For lower vertebrates,
albumin has been suggested to be important for T4 transport,
and TTR for T3 transport [8]. Binding of xenobiotics to
TH-carrying proteins is important not only because it may
disrupt TH transport but also because the proteins may
carry the xenobiotics to TH target tissues. This is espe-
cially the case for TTR, which can cross the placenta and
the blood-brain barrier [9].
Examples of compounds that are known to interfere with TH
transport proteins are hydroxylated polychlorinated biphenyls
(OH-PCBs) and hydroxylated polybrominated diphenylethers
(OH-PBDEs) [4, 10, 11]. More recently, perfluorinated com-
pounds were reported to bind to TTR [12]. By competing with
the natural ligand, TTR binders prevent proper transport of TH
and cause an increase in unbound TH which is then available
for further metabolization and excretion. Several different
in vitro assays have described the determination of the binding
potency of environmental pollutants to TTR, either based on
radiolabeled ligand competitive binding (RLBA) or on the use
of non-radiolabeled ligand competitive binding (BA, SPR,
ANSA, and FLU-TTR). The assays are described further in
detail in the Electronic Supplementary Material.
To identify TH-disrupting compounds in the environment,
the TTR-binding assay can be used in effect-directed analysis
(EDA). EDA involves a bioassay/effect-directed fractionation
of an extract followed by chemical identification and confir-
mation steps. EDAwas successfully applied to evaluate endo-
crine potencies in several water systems, e.g., in wastewater
treatment plants [13–15], rivers [13, 15–17], harbor areas [18,
19], marine sediments [20], and biota [21]. An earlier pub-
lished review describes a range of important results from
effect-directed studies, e.g., identified compounds and
pinpointed hotspots [22]. Until now the main focus in EDA
research has been on estrogenic and (anti-)androgenic activity
and only four studies have addressed thyroid hormone disrup-
tion, two in sediment extracts from water systems, i.e., in
The Netherlands [19] and in Germany [23], one in indoor dust
from Japan [24], and one in polar bear plasma [25]. In polar
bear plasma, the identified THDCs could successfully explain
almost 80 % of the observed TTR-binding potency of the
extract.
A major criticism of the EDA approach is the limited iden-
tification success rate, and a key to increase its utility is to
improve the availability and quality of databases containing
known bioactive compounds and their chemical properties. To
aid the identification of effect-causing compounds, we com-
piled a database that reports all compounds that have been
tested in the TTR-binding assay, including both active and
non-active compounds. To further explore the chemical char-
acteristics of TTR-binding compounds, the compiled dataset
was analyzed using principal component analysis (PCA) and a
set of calculated chemical descriptors.
A second aim of the paper was to use the database to assist
in the identification of THDCs in a sediment extract using the
EDA approach [26].
Methods
Database of compounds tested for their TTR-binding
potency
A database was compiled with compounds that were tested in
in vitro bioassays measuring the TTR-binding potency
(Table S1). The in vitro bioassays are described in the Elec-
tronic Supplementary Material. The literature was collected
via ScienceDirect and PubMed, and the search was limited
to compounds tested for having a direct interaction with
TTR. The relative potencies, expressed in T4 or T3 relative
effect potency (REP) values, were either extracted from the
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publications or calculated by dividing the IC50 of the natural
ligand T4 by the IC50 of the competitor, with IC50 as the
concentration that is capable of replacing 50 % of a labeled
TTR ligand from TTR. By definition, the REP of T4 and T3 is
1. Thus, compounds with higher affinity for TTR than the
natural ligand have a REP>1, and compounds with lower
affinity have a REP<1.
Chemical descriptors and principal component analysis
Of the 250 compounds in the database, 220 have been tested
for their binding affinity to human TTR. These compounds
were classified as binders (IC50>25 μM; 100 compounds)
and non-binders (IC50>25 μM; 120 compounds) and charac-
terized using 57 chemical descriptors calculated using the
Molecular Operating Environment (MOE; chemcomp.com)
software from their structures (represented by SMILES
codes). The structures of the compounds were taken from
various sources (e.g., SciFinder, PubChem) and processed
by ChemAxon JChem Standardizer under the settings of
BAdd explicit hydrogens,^ BAromatize,^ BClean 2D,^ and
BRemove fragment^ (ChemAxon JChem Version 6.1.2,
2013. ChemAxon; chemaxon.com). Descriptors were selected
for their chemical relevance, interpretability, and (hence) util-
ity for describing their major chemical variation. A complete
list with brief explanations can be found in the Electronic
Supplementary Material (Table S2). The descriptor set in-
cludes the logarithm of the octanol-water partition coefficient
(logKow), molecular polarizability, and Van derWaals volume
in combination with selected flexibility, shape, and con-
nectivity indices. In addition, molecular surface character-
istics were reflected by Bpartial equalization or orbital
electronegativity^ (PEOE) descriptors. Counts of selected
atom types, single and aromatic bonds, and some count
ratios completed the descriptor set.
Prior to the analysis, the descriptors were logarithmically
transformed (if not already log transformed) if the calcu-
lated skewness exceeded 2 to improve the normality of
the descriptors’ distributions and to minimize the impact
of extreme values.
PCAwas used to obtain an overview of the physicochem-
ical characteristics of the compounds of the database. PCA is a
latent vector-based method that compresses data into a few
orthogonal vectors, principal components (PCs), summarizing
the variation and correlation patterns in the data. Each PC
consists of two vectors where not only similarities among
objects (i.e., compounds) but also correlation patterns among
the descriptors are visualized. The score vector shows sim-
ilarities among the compounds, and the loading vector
shows the correlation pattern among the descriptors. Here,
we used the software SIMCA-P+ v13 for the multivariate
analysis (umetrics.com) and an eigenvalue of 2 to define
the number of significant PCs.
Chemical screening of TTR binders in sediment
The created TTR-binding database was used to identify
THDC in a sediment sample from a previous EDA study.
The sediment sample was collected from a polluted site in
the river Schijn, a tributary to the river Scheldt, close to Ant-
werp (Belgium). The sample, EDA methodology, and chem-
ical analysis have been described in detail elsewhere [16, 26].
In short, the sample preparation included accelerated sol-
vent extraction, gel permeation chromatography, and fraction-
ation by reversed-phase (RP) followed by normal-phase (NP)
liquid chromatography techniques. Each RP and NP fraction
was tested for its TTR-binding potency in the RLBA, de-
scribed in detail elsewhere [4, 12]. The assay has been vali-
dated in-house, showing a coefficient of variation of less than
8 % over time. The limit of detection is set to 20 % of the
binding capacity (in the range of 16 nM T4). To improve the
detection limit, the 125I-T4 is always purified from free labeled
iodine before incubation [12].
The identification of active compounds is facilitated by a
decrease in complexity of the sample extract, which is obtain-
ed by repeated fractionation of samples with TTR-binding
activity. Nevertheless, still many compounds showed to be
present in the active fractions. All NP fractions were screened
with GC-MS (GC Agilent 6890 with a MS, Agilent 5973),
equipped with an SGE-BPX5 column (25 m, 0.22 mm i.d.,
0.3 μm film thickness), using splitless injection and full-scan
(m/z 50–650) data acquisition in electron impact (EI) mode
[26], and with LC-MS using a linear quadrupole ion trap-
Orbitrap (LTQ-Orbitrap) mass spectrometer (Thermo Elec-
tron) with an Xbridge C18-LC column (Waters, 100×
2.1 mm, 3.5 μm) equipped with an electron spray ionization
source (ESI) operating in positive mode (negative mode was
evaluated but is not reported due to lack of interesting results)
[16]. Survey full-scan MS spectra (from m/z 50 to 600) were
acquired using the Orbitrap with a resolution of 30,000.
GC-MS spectra were deconvoluted using the Automated
Mass Spectral Deconvolution and Identification System
(AMDIS version 2.64) and compared with reference spectra
in the National Institute of Standards and Technology (NIST
version 02) main mass spectral database (match factor ≥70 %)
for tentative identification [26]. The identification using LC
coupled to high-resolution LTQ-Orbitrap instrumentation was
described in detail elsewhere [16].
Results and discussion
Chemical characterization of TTR binders
In total, 427 entries representing 250 compounds and techni-
cal mixtures were included in the database. All compounds
have been tested for their binding potency to TTR, derived
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from seven different species, human (recombinant and puri-
fied, 305 entries), birds (chicken [Gallus gallus] and gull
[Larus hyperboreus and Larus argentatus], 26 entries), fishes
(salmon [Onchorhynchus masou] and sea bream, 51 entries),
and amphibians (Rana catesbeiana and Xenopus laevis, 45
entries).
Among the 250 compounds of the database, 222 com-
pounds were derived from the literature and 33 compounds
were tested in the present study, of which 5 have been ana-
lyzed earlier for their potency to bind to TTR. The distribution
of the most common characteristics of the 250 entities is illus-
trated in a Venn diagram (Fig. 1); 198 compounds are haloge-
nated (79 %); 195 contain ≥1 aromatic ring system (78 %);
106 compounds are hydroxylated (42 %); 88 compounds are
aromatic, halogenated, and hydoxylated (35 %); and 15 (6 %)
of the compounds lack the three main characteristics, i.e.,
aromatic, hydroxylated, and halogenated. Based on knowl-
edge of the structure of known environmental THDCs, halo-
genated aryl compounds, with a hydroxy group at a position
similar to the natural ligand thyroxine (T4), are traditionally
suspected to have TTR-binding potencies. Compounds with
carboxylic acids were not considered as hydroxylated because
these acids are most likely not protonated under natural con-
ditions. One hundred forty-four of the tested compounds
(58 %) were able to bind to TTR, and 52 (21 %) were more
potent than the natural hormone T4 (REP>1). Among the 52
most potent compounds, 48 were aromatic, hydroxylated, and
halogenated.
Some differences in the TTR-binding potency between
species have been reported [27, 28] (see examples in
Table S1). Although the primary structure of TTR has been
conserved for 400 million years, some changes in amino acid
residues of the N-terminal region have been identified [29].
These structural modifications affect the affinity of the TTR-
binding site not only to T4 but also to exogenous compounds,
and explain the differences in the TTR-binding potency of
compounds reported between species.
A PCA was applied to view the chemical variation of the
220 compounds tested for their binding affinity to human
TTR. Four significant principal components (PCs) could ex-
plain 85 % of the chemical variation, of which the first two
PCs explained 64% (Fig. 2—score plot). In brief, the two first
PCs display a separation into three groups covering aromatic
and halogenated compounds (group 1, consisting of binders
and non-binders), fatty acids (group 2, non-binders), and
perfluorinated compounds (group 3, binders and non-binders).
Each group is spread in the second dimension (PC2) accord-
ing to polarity and molecular size (Figure S1—loading plot).
The majority of active compounds is clustered (the left
cluster), and these have negative PC1 values and moderate
PC2 values. In this cluster, the small phenols are inactive
as well as the large brominated aromatics (Fig. 2). The
PCA clearly illustrates the disparate chemical properties of
the perfluorinated compounds (the right cluster) in relation
to the majority of active compounds which indicates dis-
similar structure-activity relationships. Noteworthy are also
the unique chemical profiles of the endogenous hormone
(T4) and the TTR binders tetrabromobisphenol A bis(2,3--
dibromopropyl ether) TBBPA-DBPE and 4-nonylphenol
(technical mixture). The reported activity of TBBPA-DBPE
could, however, be due to contamination with its potent pre-
cursor TBBPA [30].
Screening of THDCs in a sediment sample
TTR-binding activity in the sediment extract
An EDA study of sediment was conducted to determine the
TTR-binding potency and to identify the active compounds.
Before the sediment extract was fractionated, the extract
showed a total TTR-binding potency of 1000 pmol T4
equivalents/g dry weight (d.w.) of sediment. Using reversed-
phase (RP) LC, the extract was fractionated into five fractions
with an increasing octanol-water partitioning coefficient (Kow)
(RP1–RP5), of which RP3 showed the highest TTR-binding
affinity (i.e., 235 pmol T4 equivalents/g d.w.; first column in
Fig. 3). Active RP fractions were further fractionated by
normal-phase (NP) LC into eight fractions with increasing
polarity. For the active RP3 fraction, this resulted in three
active NP fractions, i.e., NP 5–7. Elevated TTR-binding po-
tency was also found in RP2NP7. The summarized TTR-
binding potency of the individual fractions was ca 50 % of
the total TTR-binding potency measured in the unfractionated
extract. This lower value may be explained by the separation
of active compound groups over multiple fractions, resulting














Fig. 1 A Venn diagram illustrating the distribution of the three main
chemical structure characteristics, i.e., halogenation, aromaticity, and
the presence of a hydroxyl group, of the 250 compounds tested in the
TTR-binding assays listed in Table S1 (Electronic Supplementary Mate-
rial). In brackets are the total numbers of compounds belonging to each
characteristic or to none of the three characteristics
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of quantification of the assay. The recovery of the potency of
TTR binding was tested by pooling the NP fractions into the
original composition and performing the assay again. It was
confirmed that the decrease in potency after fractionation was
not due to loss of compounds in the fractionation step as the
initial potency was recovered in the pooled NP fractions (data
not shown).
Identification of THDCs in active fractions
To identify which compounds were present in the active frac-
tions, LTQ-Orbitrap and GC-MS analyses were carried out,
from which 43 tentatively identified compounds were derived
(Table 1). The LTQ-Orbitrap results were evaluated using the
identification strategy described earlier [16]. From a total
number of 6503 base peak framed masses (SIEVE), 337 ac-
curate masses were selected for investigation. Criteria were
that the peak shape was normally distributed and the mass
should have an intensity 100 times higher than the adjacent
control (non-active) fraction. It was not possible to perform a
mass fragmentation confirmation to establish the match factor
of the tentatively identified compounds in the LTQ-Orbitrap
due to low intensities. Instead, the accurate mass and the iso-
tope pattern were used for tentative identification. With this
strategy, eight compounds could be tentatively identified
which were present in the NIST library and then analytically
confirmed by retention time using standard compounds
(marked LC in Table 1).
GC-MS screening using AMDIS and the NIST library re-
sulted in the tentative identification of 39 compounds having a
>70 % match factor (marked GC in Table 1). As this was a
complex matrix, mass shifts and interfering effects such as ion
suppression may have occurred, possibly altering the chro-
matographic profile. Therefore, also compounds suggested
from the NIST library search with a match factor below
70 % could be of interest. Eight NIST library search indicated
compounds, with a match factor between 50 and 70 %, are
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Fig. 2 PCA score plot showing
principal component 1 (t1) versus
2 (t2). Compounds marked in red
are reported with IC50 values
≤25 μM and in green >25 μM in
the human TTR assay.
Compounds are abbreviated
according to Table S1



















Fig. 3 The TTR-binding activity measured in the reversed-phase (RP)
fractions and the normal-phase (NP) fractions. The activity (pmol T4
equivalents/g dry sediment) is given in brackets for each fraction
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Table 1 Tentatively identified compounds (analyzed with GC-MSwith a
match factor ≥70 % in the NIST library, or with LC-LTQ-Orbitrap on accu-
rate mass) present in TTR-binding active fractions (RP=reversed-phase and
NP=normal-phase fractionation) in a sediment sample. The span of the log
Kow of the RP fractions RP2, RP3, and RP4 is in the order of 2–4, 4–6, and
6–9 respectively. In addition, eight compounds indicated in the NIST library
with amatch factor of 50–70% and the additionally tested compounds in the
TTR-binding assay are listed at the end of the table
Fraction CAS Name LC/GC TTR-binding activity
RP2NP6 123-52-85 (1H-Benzoimidazol-2-yl)-diphenyl-methanol GC No info
4237-44-9 2-(1-Phenylethyl)-phenol GC No info
23966-56-5 2-Amino-3,3-diphenyl-phthalimidine GC No info
NIST-307688 4-Methoxyphenyl ester 2-fluorobenzoic acid GC No info
85-68-7 Butylbenzyl phthalate GC Active [28], not active (TS)
127-63-9 Diphenyl sulfone GC Not active (TS)
RP2NP7 137909-40-1 Bis(1-chloro-2-propyl)(3-chloro-1-propyl) phosphate GC No info
115-86-6 Triphenyl phosphate GC Not active (TS)
13674-84-5 Tris(2-chloro-iso-propyl) phosphate GC Not active (TS)
1067-98-7 Tris(3-chloropropyl) phosphate GC No info
120-58-1 Isosafrole LC Not active (TS)
548-39-0 Perinaphthenone LC/GC Not active (TS)
959-28-4 (2E)-1,4-Diphenyl-2-butene-1,4-dione LC Not active (TS)
94-62-2 Piperine LC Not active (TS)
RP3NP4 225-51-4 Benz[c]acridine GC No info
1018-97-9 Bis(2-methylphenyl)-methanone GC No info
1222-05-5 Galaxolide LC/GC Not active (TS)
RP3NP5 1159-86-0 1,2-Dibenzoyl benzene GC No info
3770-82-9 1,3-Dibenzoyl benzene GC No info
3016-97-5 1,4-Dibenzoylbenzene GC No info
75694-46-1 2,3-Diphenylbenzo-1,4-dioxin GC No info
2219-84-3 2-Methyl-4-(1,1,3,3-tetramethylbutyl)-phenol GC Not active (TS)
140-66-9 4-(1,1,3,3-Tetramethylbutyl)-phenol GC Not active (TS)
80-46-6 4-tert-Pentyl phenol GC Not active (TS)
5635-50-7 Hexestrol GC No info
21145-77-7 Tonalide LC/GC Not active (TS)
68140-48-7 Traseolide LC/GC Not active (TS)
RP3NP5-6 82-05-3 7H-Benz[de]anthracen-7-onea LC Not active (TS)
NIST-317319 n-[4-(Phenylamino)phenyl]-benzamide GC No info
104-40-5 p-Nonylphenol technical mixture, 8 identified peaks GC Active (TS and [40, 25])
RP3NP6 20760-63-8 1-(p-Fluorophenyl)-anthraquinone GC No info
NIST-307638 3,4-Dichlorophenyl ester p-anisic acid GC No info
64436-60-8 4′-Propoxy-2-methylpropiophenone GC No info
NIST-315373 Di(3-methylphenyl) phthalate GC No info
84-74-2 Di-n-butyl phthalate GC Active [28], not active (TS)
NIST-315190 Ethyl hex-2-yn-4-yl phthalate GC No info
13556-73-5 n-Benzyl-n′-phenyl-p-phenylenediamine GC No info
3380-34-5 Triclosan GC Active (TS)
RP3NP7 5875-45-6 2,5-Bis(1,1-dimethylethyl)-phenol GC No info
RP4NP6 80-97-7 Cholestanol GC No info
360-68-9 Coprostanol GC No info
559-74-0 Friedelan-3-one GC No info
1617-70-5 Lupenone GC No info
Compounds indicated in the NIST library (match factor 50–70 %)
Multiple 101-53-1 4-(Phenylmethyl)-phenol GC Not active (TS)
Multiple 1806-26-4 4-Octylphenol GC Active [28], not active (TS)
5630 J.M. Weiss et al.
Out of the tentatively identified compounds in the sediment
sample, only two could be confirmed as TTR binders, i.e.,
triclosan and the technical mixture of nonylphenol. Triclosan
is an antibacterial agent, which has shown to cause a dose-
dependent decrease in total T4 in a 4-day oral exposure study
with rats [31]. TTR binding could be an explanation for this
observed decrease of free circulating T4. Nonylphenol is a
detergent, which is used in a technical mixture and also a
degradation product of nonylphenol polyethoxylate surfac-
tants. Eight different isomers were distinguished in the GC
chromatogram, consisting of linear and differently branched
isoforms typically present in a technical mixture. An earlier
study confirmed that branched nonylphenol can bind to hu-
man TTR, whereas no binding was observed for linear
nonylphenol [25]. Nonylphenol has been reported before as
a binder to TTR from several species (Table S1), but these
studies did not report which form of nonylphenol was tested.
Earlier analysis of exactly the same sample reported a triclo-
san concentration of 26 ng/g d.w. sediment and a nonylphenol
concentration of 210 ng/g d.w. [32]. Based on their REP
values and concentrations, these two compounds could ex-
plain less than 1 % of the observed TTR-binding potency in
the unfractionated extract. Only four of the compounds in
Table 1 have been studied earlier for their TTR-binding po-
tency, i.e., the nonylphenol, two phthalates (butylbenzyl
phthalate and dibutyl phthalate), and octylphenol. The
phthalates and octylphenol were reported to exhibit weak
TTR binding in RLBA with salmon and frog TTR [28]
(Table S1). In the present study, however, these compounds
showed no binding to human TTR. The four compounds pres-
ent in fraction RP4NP6 are a group of natural compounds
including plant steroids (Table 1). Although the log Kow
values are slightly too high (~8.8) for the corresponding
fraction (log Kow 6–8), it is likely that these compounds are
present in the sediment extract. The compounds are more like-
ly to have an androgen- or estrogen-disrupting potential than
TTR-binding activity, considering the structural similarities
with steroid hormones.
In addition, the last seven compounds included in Table 1
were tested for their TTR-binding potency, due to their similar
properties (aromatic, halogenated, and hydroxylated) as al-
ready tested compounds. Bisphenol A is a high-production-
volume chemical (HPVC) used in plastics and epoxy resins,
with high concern for its endocrine-disrupting properties,
though no TTR-binding activity was observed. The musk
compounds, celestolide, phantolide, ambrette, and ketone,
did not bind to TTR. The antiseptic agent triclocarban is a
common additive in soaps and other personal care products,
and also for triclocarban, no TTR-binding activity was found.
Diclofenac is a non-steroidal anti-inflammatory drug
(NSAID) used at high volume and is known to pass through
the wastewater treatment plants and enter the water environ-
ment [33]. Diclofenac bound to TTR with a T4 REP value of
0.032 (Table S1). Diclofenac is also known for its binding
potency to TTR from earlier studies on NSAIDs as anti-
amyloid compounds [34]. Anti-amyloid genesis drugs are
small molecules that stabilize TTR by binding to its TH
binding sites (based on an in vitro fibril formation assay).
Diclofenac is aromatic and chlorinated in ortho-positions
and has a carboxylic acid moiety on the second aromatic
ring. The binding pocket of TTR is well defined, and the
size and shape of the ligand are important for the affinity
[35]. It has been shown that biphenyls, dibenzofurans,
diphenylethers, stilbene, and flavone are basic structures with
optimal size that can be functionalized with substituents to
interact in the pocket [36]. The compounds listed in Table 1
Table 1 (continued)
Fraction CAS Name LC/GC TTR-binding activity
Multiple 26444-49-5 Cresyldiphenyl phosphate GC Not active (TS)
Multiple 3055-96-7 Hexaethyleneglycol monododecyl ether GC Not active (TS)
Multiple 1338-24-5 Naphthenic acid GC Not active (TS)
Multiple 111-02-4 Squalene GC Not active (TS)
Multiple 115-96-8 Tris(2-chloro-ethyl) phosphate GC Not active (TS)
Multiple 78-42-2 Tris(2-ethylhexyl) phosphate GC Not active (TS)
Additional tested compounds (not tentatively identified in the sediment sample)
80-05-7 Bisphenol A Not active (TS and [5])
13171-00-1 Celestolide Not active (TS)
15323-35-0 Phantolide Not active (TS)
83-66-9 Musk ambrette Not active (TS)
81-14-1 Musk ketone Not active (TS)
101-20-2 Triclocarban Not active (TS)
15307-86-5 Diclofenac Active (TS)
No info no available literature on TTR-binding activity and not tested in this study, TS this study
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fit well into that description. Of the 58 compounds in Table 1,
10 compounds are halogenated (17 %), 45 have aromatic ring
systems (76 %), and 15 are hydroxylated (26 %).
EDA strategy
The identification strategy presented here is limited by several
set criteria (e.g., the intensity ratio active/non-active control
fraction >100, match factor >70 %, standard availability, etc.).
Another approach that currently receives significant attention
is Bsuspect screening^ using databases such as the one pre-
sented here. This strategy screens all masses but only the hits
in the database are being further evaluated, which is an essen-
tial difference in comparison with the non-target screening
strategy presented here. In addition, the prerequisite for the
compound to be present in the NIST library limits the possi-
bilities to identify active compounds which are metabolites
and at low concentrations. Hence, future research is needed
to aid the identification of the key toxicants present in the
environment by developing more sensitive strategies for the
chemical identification in the framework of EDA. Most cru-
cial is the capability to exclude the presence of background
compounds without losing the compounds of interest. One
promising approach is the application of high-resolution
fractionation techniques [37] or the application of the
two-dimensional separation with a LC×LC system [38].
This together can improve the EDA efficiency regarding
throughput and success rate. Still, it is important to get a
better understanding and overview of chemical structures
and effect-based correlations to carry out EDA in the
search for key toxicants in our environment. Hopefully,
the database presented here is one step in the direction
for improved THDC identification.
Conclusion
Table S1 in the Electronic Supplementary Material summa-
rizes the state of knowledge regarding the TTR-binding
capacity of a wide range of chemical compounds, e.g.,
environmental contaminants, pesticides, pharmaceuticals,
metabolites, etc. The table is presented to facilitate future
EDA studies to identify TTR binders and non-binders.
Here, we have demonstrated an identification strategy in
identifying THDCs in a sediment extract with TTR-binding
potency. Two compounds, triclosan and nonylphenol techni-
cal mixture, could be confirmed to have contributed to the
observed activity in the TTR-binding assay; however, only
1 % of the activity could be explained by the presence of these
two compounds. The chemical properties in Table S1 are bi-
ased towards aromatic, halogenated, and hydroxylated com-
pounds, which are structural features of the natural hormone
thyroxine. The PCA illustrated this in the first PCs which
displayed a separation of aromatic and halogenated com-
pounds (active and non-active) from fatty acids (non-active)
and perfluorinated compounds (active). In addition, the data-
base presented here was used to further evaluate the structure
relationship with the TTR-binding activity and a model was
developed to predict the potential of contaminants to bind to
TTR [39]. Here, it is demonstrated that more data on TTR-
binding compounds is needed to cover the potential binding
potency of compounds without these typical characteristics.
Also, more sensitive identification strategies combining, e.g.,
novel fractionation techniques and accurate chemical analysis
instruments are needed, without increasing the already sub-
stantial workload on the identification step.
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